Nykode Therapeutics ASA

Nykode Therapeutics ASA

0.27
EUR
0.00
(0.00%)
-0.05EPS
91.76MMarket Cap
Nov 25Next Earn

Total Valuation

EUR

As of June 30, 2026, Nykode Therapeutics ASA carries a market capitalization of 91.76M, placing it among publicly traded companies globally. Its enterprise value stands at 54.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap91.76M
Enterprise Value54.12M

Important Dates

Nykode Therapeutics ASA's next confirmed earnings release is scheduled for November 25, 2026.

Earnings Date11/25/2026

Share Statistics

As of June 30, 2026, Nykode Therapeutics ASA has 326.55M shares outstanding.

Shares Outstanding326.55M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio1.30
P/TBV Ratio1.31
P/FCF Ratio-4.54
P/OCF Ratio-4.54

Financial Position

As of June 30, 2026, Nykode Therapeutics ASA maintains a current ratio of 11.52, meaning it holds 11.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.22, indicating elevated leverage, while an interest coverage ratio of -250.25 demonstrates limited ability to service its debt obligations.

Current Ratio11.52
Quick Ratio10.71
Debt / Equity2.22
Debt / EBITDA-0.07
Interest Coverage-250.25

Financial Efficiency

Over the twelve months ended June 30, 2026, Nykode Therapeutics ASA posted a negative return on equity (ROE) of -25.07, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -23.22, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 79.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-25.07
Return on Assets (ROA)-23.22
Employee Count79.00

Taxes

EUR

Over the twelve months ended June 30, 2026, Nykode Therapeutics ASA recorded an income tax benefit of -1.17M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -21.26M and -20.09M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-1.17M

Stock Price Statistics

EUR

As of the close on November 17, 2026, Nykode Therapeutics ASA's stock has gained approximately 65.76% over the past 52 weeks. The 50-day moving average sits at 0.31, while the 200-day moving average is 0.30.

52-Week Price Change65.76%
50-Day Moving Average0.31
200-Day Moving Average0.30

Income Statement

EUR

Over the twelve months ended June 30, 2026, Nykode Therapeutics ASA generated - - in revenue and converted that into -20.09M in net income, yielding earnings per share of -0.05. EBITDA reached -22.34M, while operating income came in at -24.20M.

Operating Income-24.20M
Pretax Income-21.26M
Net Income-20.09M
EBITDA-22.34M
EBIT-24.20M
Earnings Per Share (EPS)-0.05

Balance Sheet

EUR

As of June 30, 2026, Nykode Therapeutics ASA holds 39.21M in cash and equivalents against 1.56M in total debt, resulting in a net debt position of -39.21M. Total book value stands at 70.36M, with working capital of 38.52M providing operational flexibility.

Cash & Cash Equivalents39.21M
Total Debt1.56M
Net Debt-39.21M
Equity (Book Value)70.36M
Book Value Per Share0.22
Working Capital38.52M

Cash Flow

EUR

Nykode Therapeutics ASA produced -23.76M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -875.30 in capital expenditures, free cash flow totaled -23.76M - equivalent to -0.06 per share.

Operating Cash Flow-23.76M
Capital Expenditures-875.30
Free Cash Flow-23.76M
FCF Per Share-0.06

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -22.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Nykode Therapeutics ASA shareholders.

Shareholder Yield1.20
FCF Yield-22.01

Stock Splits

Nykode Therapeutics ASA's most recent stock split took place on July 7, 2020 with a 1:5 split ratio.

Last Split Date7/7/2020
Split Ratio1:5

Scores

As of June 30, 2026, Nykode Therapeutics ASA has an Altman Z-Score of 10.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score10.00